Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
The SURMOUNT-5 head-to-head trial found tirzepatide produced significantly greater mean weight reduction than semaglutide at 72 weeks (20.2% vs. 13.7%) in adults with obesity, establishing the first direct randomized comparison between the two leading GLP-1-class therapies for chronic weight management.
This is a summary. The reporting is New England Journal of Medicine's, and the link below goes to the original article.